TICKERNERD
Menu
CMPXCMPXHealthcare · Biotechnology

CMPX Stock Forecast: Compass Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.00
−2.44% on the day

The 15 Wall Street analysts covering Compass Therapeutics, Inc. hold a median 12-month price target of $7 — +250.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$360.2M
Ticker Nerd rank
32 / 100
Median analyst target
$7.00
Analysts covering
15
Revenue$0.0
Operating income−$27.0M
Net income−$25.2M
Free cash flow−$14.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.6%
1M
−9.1%
YTD
−62.8%
1Y
−43.3%
From 52W high
−70.1%
From 52W low
+19.8%
$1.67
$6.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CMPX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Compass Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
58
Quality
57
Value
55
Accruals
54
Growth
47
Issuance
39
Revisions
36
Volatility
34
Momentum
21

Size (58): Smaller than most of the companies we track.

Momentum (21): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CMPX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CMPX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26CMPXHigh $24.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $5.00Median $7.00High $24.00

The green dot is the last close — the median target sits +250.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026Piper SandlerMaintainsOverweight$4.00 → $6.00
28 Apr 2026Canaccord GenuityMaintainsBuy—
28 Apr 2026Canaccord GenuityMaintainsBuy$13 → $7.00
28 Apr 2026CitizensReiteratesMarket Outperform—
28 Apr 2026CitizensReiteratesMarket Outperform$10
27 Apr 2026D. Boral CapitalMaintainsBuy$30
27 Apr 2026D. Boral CapitalMaintainsBuy—
27 Apr 2026HC Wainwright & Co.ReiteratesBuy$24
27 Apr 2026HC Wainwright & Co.ReiteratesBuy—
24 Mar 2026GuggenheimReiteratesBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026William BlairInitiatesOutperform—
3 Dec 2025Canaccord GenuityInitiatesBuy—
3 Dec 2025Cantor FitzgeraldInitiatesOverweight—
3 Dec 2025CitizensInitiatesMarket Outperform—
5 Nov 2025D. Boral CapitalMaintainsBuy—
6 Oct 2025LifeSci CapitalInitiatesOutperform—
12 Aug 2025D. Boral CapitalMaintainsBuy—
12 Aug 2025GuggenheimMaintainsBuy—
1 July 2025Raymond JamesReinstatesOutperform$9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CMPX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CMPX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Compass Therapeutics, Inc. returned −43.3% against +17.5% for the S&P 500, dividends included.

CMPX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26CMPXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CMPX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
11
Fundamentals

Compass Therapeutics, Inc. (CMPX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.8×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 43% of US stocks

EV / EBITDA
−2.3×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−56.7%

Higher than 20% of US stocks

Return on assets
−33.0%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Compass Therapeutics, Inc. (CMPX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Compass Therapeutics, Inc. has a market value of $360.2M and an enterprise value of $189.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$73.4M.

  • Diluted earnings per share, trailing twelve months: $−0.40.

  • Free cash flow in the twelve months to 30 June 2026: −$56.4M.

  • Shares outstanding: 180.1M.

  • Trailing P/E: −4.8×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Compass Therapeutics, Inc. employs 39 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

CMPX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CMPXCompass Therapeutics, Inc.$360.2M
32
PALIPalisade Bio, Inc.$359.0M
36
OBIOOrchestra Biomed Holdings, Inc.$358.1M
38
RCKTRocket Pharmaceuticals, Inc.$362.5M
55
PRLDPrelude Therapeutics, Inc.$365.6M
95
INDPIndaptus Therapeutics, Inc.$369.1M
23
SIONSionna Therapeutics, Inc.$350.3M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Compass Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CMPX news & analysis

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

GlobeNewsWire · 6 Aug 2026positive

Compass Therapeutics expects feedback from the FDA this quarter on the Phase 2/3 COMPANION-002 data for tovecimig in biliary tract cancer, ahead of a potential BLA filing later this year. The tovecimig data was also selected for an oral presentation at the 2026 ESMO Congress in October.

Why it matters — A CMPX watcher would care because the expected FDA feedback and potential BLA filing are key near-term regulatory milestones for tovecimig, the company's lead bispecific antibody candidate.

FAQ

Frequently asked questions about CMPX stock

What is the CMPX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Compass Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CMPX stock a buy right now?

Of the 15 analysts covering Compass Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compass Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CMPX?

As at 12 Sept 2026, Compass Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (58 of 100).

Will CMPX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +250.0% from the last close, and Ticker Nerd's factor model ranks Compass Therapeutics, Inc. 32 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CMPX stock forecast for 2030?

No analyst covering Compass Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMPX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $24 over the next 12 months.

How has CMPX stock performed over the past year?

Compass Therapeutics, Inc. returned -43.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Compass Therapeutics, Inc. do?

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer.

What is the latest news on CMPX?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update". Compass Therapeutics expects feedback from the FDA this quarter on the Phase 2/3 COMPANION-002 data for tovecimig in biliary tract cancer, ahead of a potential BLA filing later this year. The tovecimig data was also selected for an oral presentation at the 2026 ESMO Congress in October.

Company

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. The company concentrates on oncology programs that target angiogenesis, immune activation, and tumor-driven immunosuppression, with product candidates designed to address critical biological pathways involved in anti-tumor responses. Its current pipeline includes bispecific and monoclonal antibody programs such as tovecimig, CTX-471, CTX-8371, and CTX-10726, reflecting a platform built around antibody discovery and engineering. Compass Therapeutics uses proprietary technologies to identify and optimize therapeutic leads and to create modular, manufacturable bispecific candidates. The company plays a specialized role in the biotechnology market by advancing immuno-oncology research into clinical development, with a focus on solid tumors and other cancer indications.

CEO Dr. Thomas J. Schuetz M.D., Ph.D. · 39 employees · United States · https://www.compasstherapeutics.com